TERAZOSINE MYLAN 5 mg, tablet 28 tablets
Active ingredients: Terazosin hydrochloride dihydrate, Terazosin
Commercialized according to BDPMDispensing in France: Prescription only
Tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TERAZOSINE MYLAN 5 mg, comprimé
- Pharmaceutical form
- comprimé
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC-Aluminium de 28 comprimé(s)
- Marketing authorisation holder
- MYLAN SAS
- Reimbursement according to BDPM
- 30%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 1 Mar 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65566430CIP73574552CIP133400935745521Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TÉRAZOSINE BASEcomprimé | 5,000 mg · un comprimé | FT |
| CHLORHYDRATE DE TÉRAZOSINE DIHYDRATÉcomprimé | 5,935 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.